ADGRE3

Across TCGA pan-cancer cohorts, ADGRE3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADGRE3 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADGRE3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADGRE3 expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where ADGRE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.361	0.984	.024	15	view →
HNSC	DFS	Median	IV	0.453	0.900	.024	10	view →
LUAD	DFS	Median	All	0.549	0.730	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADGRE3–PDAC (DFS)

Open the PDAC breakdown →